Evidence map›Paper›PMID 20852633›Full record

ArticleNature genetics2010

Common variants at 19p13 are associated with susceptibility to ovarian cancer.

Kelly L Bolton, Jonathan Tyrer, Honglin Song, Susan J Ramus, Maria Notaridou, Chris Jones, Tanya Sher, Aleksandra Gentry-Maharaj, Eva Wozniak, Ya-Yu Tsai and 110 more

Erratum issuedOpen access · greenAbstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature genetics, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 171 papers, 11 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
171citing papers in PubMed, 11 pooled it
30.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

171 citing papers in PubMed, 11 syntheses or guidelines pooled it, 256 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Network-Based Integration of GWAS and Gene Expression Identifies a HOX-Centric Network Associated with Serous Ovarian Cancer Risk.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2015
    Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Combined and interactive effects of environmental and GWAS-identified risk factors in ovarian cancer.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2013
    Pooled it
  9. Pooled it
  10. Guideline
  11. Pooled it
  12. Trial
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

111 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

120 authors at 20 institutions in 11 countries.

Kelly L BoltonDepartment of Oncology, University of Cambridge, Cambridge, UK.
Jonathan Tyrer
Honglin Song
Susan J Ramus
Maria Notaridou
Chris Jones
Tanya Sher
Aleksandra Gentry-Maharaj
Eva Wozniak
Ya-Yu Tsai
Joanne Weidhaas
Daniel Paik
David J Van Den Berg
Daniel O Stram
Celeste Leigh Pearce
Anna H Wu
Wendy Brewster
Hoda Anton-Culver
Argyrios Ziogas
Steven A Narod
Douglas A Levine
Stanley B Kaye
Robert Brown
Jim Paul
James Flanagan
Weiva Sieh
Valerie McGuire
Alice S Whittemore
Ian Campbell
Martin E Gore
Jolanta Lissowska
Hanna P Yang
Krzysztof Medrek
Jacek Gronwald
Jan Lubinski
Anna Jakubowska
Nhu D Le
Linda S Cook
Linda E Kelemen
Angela Brooks-Wilson
Angela Brook-Wilson
Leon F A G Massuger
Lambertus A Kiemeney
Katja K H Aben
Anne M van Altena
Richard Houlston
Ian Tomlinson
Rachel T Palmieri
Patricia G Moorman
Joellen Schildkraut
Edwin S Iversen
Catherine Phelan
Robert A Vierkant
Julie M Cunningham
Ellen L Goode
Brooke L Fridley
Susan Kruger-Kjaer
Jan Blaeker
Estrid Hogdall
Claus Hogdall
Jenny Gross
Beth Y Karlan
Roberta B Ness
Robert P Edwards
Kunle Odunsi
Kirsten B Moyisch
Julie A Baker
Francesmary Modugno
Tuomas Heikkinenen
Ralf Butzow
Heli Nevanlinna
Arto Leminen
Natalia Bogdanova
Natalia Antonenkova
Thilo Doerk
Peter Hillemanns
Matthias Dürst
Ingo Runnebaum
Pamela J Thompson
Michael E Carney
Marc T Goodman
Galina Lurie
Shan Wang-Gohrke
Rebecca Hein
Jenny Chang-Claude
Mary Anne Rossing
Kara L Cushing-Haugen
Jennifer Doherty
Chu Chen
Thorunn Rafnar
Soren Besenbacher
Patrick Sulem
Kari Stefansson
Michael J Birrer
Kathryn L Terry
Dena Hernandez
Daniel W Cramer
Ignace Vergote
Frederic Amant
Diether Lambrechts
Evelyn Despierre
Peter A Fasching
Matthias W Beckmann
Falk C Thiel
Arif B Ekici
Xiaoqing Chen
Australian Ovarian Cancer Study Group
Australian Cancer Study (Ovarian Cancer)
Ovarian Cancer Association Consortium
Sharon E Johnatty
Penelope M Webb
Jonathan Beesley
Stephen Chanock
Montserrat Garcia-Closas
Tom Sellers
Douglas F Easton
Andrew Berchuck
Georgia Chenevix-Trench
Paul D P Pharoah
Simon A Gayther
National Institutes of Health · USUniversity of Cambridge · GBMayo Clinic · USUniversity of Hawaiʻi at Mānoa · USUniversity of Southern California · USdeCODE Genetics (Iceland) · ISQIMR Berghofer Medical Research Institute · AUUniversity College London · GBCedars-Sinai Medical Center · USHelsinki University Hospital · FIInstitute of Cancer Research · GBMedizinische Hochschule Hannover · DEMoffitt Cancer Center · USRoswell Park Comprehensive Cancer Center · USAlberta Health Services · CABrigham and Women's Hospital · USGerman Cancer Research Center · DEBC Cancer Agency · CACentre for Human Genetics · GBFred Hutch Cancer Center · US

Funding

Two-Spirit Films in Indigenous Cancer HealthP30CA016056 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI MARK G FRATTINI · 1985 to 2026
$116.6M
Use of microfluidic tumor cultures to enable clinical trials of therapies for ovarian cancerP50CA136393 · NCI · MAYO CLINIC ROCHESTER · PI Zhenkun Lou · 2009 to 2026
$37.0M
Novel Serum, Plasma, and Urine Biomarkers of Ovarian CanP50CA105009 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI CRAMER, DANIEL WILLIAM · 2004 to 2010
$13.3M
Haplotype-Based Genome Screen for Ovarian Cancer LociR01CA114343 · NCI · H. LEE MOFFITT CANCER CTR & RES INST · PI SELLERS, THOMAS A · 2007 to 2011
$7.5M
OVARIAN CANCER RISK AND HYPERGONADOTROPIC HYPOGONADISMR01CA054419 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI CRAMER, DANIEL WILLIAM · 1992 to 2007
$5.9M
COLLABORATIVE STUDY OF OVARIAN CANCER IN TWO RISK GROUPSR01CA058598 · NCI · UNIVERSITY OF HAWAII AT MANOA · PI GOODMAN, MARC T · 1993 to 2012
$4.6M
Epidemiology of Ovarian Cancer:New HypothesesR01CA087538 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI ROSSING, MARY ANNE · 2002 to 2006
$3.5M
Steroid Hormone Genes and Ovarian Cancer RiskR01CA112523 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI ROSSING, MARY ANNE · 2006 to 2010
$3.3M
HEREDITARY BREAST CANCER--GENETIC AND MOLECULAR STUDIESR01CA058860 · NCI · UNIVERSITY OF CALIFORNIA-IRVINE · PI ANTON-CULVER, HODA A · 1994 to 2008
$3.1M
Regulatory T Cell Function in Ovarian CancerR01CA126841 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI MOYSICH, KIRSTEN B. · 2009 to 2013
$3.0M
Genetic Variation in the NF-kappaB Pathway and Ovarian Cancer EtiologyR01CA122443 · NCI · MAYO CLINIC ROCHESTER · PI GOODE, ELLEN L. · 2007 to 2012
$2.7M
HEREDITARY BREAST CANCER--GENETIC AND MOLECULAR STUDIESU01CA058860 · NCI · UNIVERSITY OF CALIFORNIA IRVINE · PI ANTON-CULVER, HODA A. · 1997 to 2002
$2.5M
Cancer Research UK 10118Cancer Research UK 10119Cancer Research UK 10124Cancer Research UK 11022Cancer Research UK A10119Cancer Research UK A10124Intramural NIH HHS Z99 CA999999Medical Research Council G0801875NCI NIH HHS CA58860NCI NIH HHS CA92044NCI NIH HHS K07 CA092044NCI NIH HHS K07 CA143047NCI NIH HHS N01CN55424NCI NIH HHS N01 PC035137NCI NIH HHS P30 CA016056NCI NIH HHS P50 CA105009NCI NIH HHS P50CA105009NCI NIH HHS P50 CA136393NCI NIH HHS R01 CA054419NCI NIH HHS R01CA054419NCI NIH HHS R01 CA058598NCI NIH HHS R01 CA058860NCI NIH HHS R01 CA087538NCI NIH HHS R01 CA112523NCI NIH HHS R01CA112523NCI NIH HHS R01 CA114343NCI NIH HHS R01CA114343NCI NIH HHS R01 CA122443NCI NIH HHS R01CA122443NCI NIH HHS R01 CA126841NCI NIH HHS R01CA126841-01NCI NIH HHS R01CA16056NCI NIH HHS R01CA58598NCI NIH HHS R01CA61107NCI NIH HHS R01CA71766NCI NIH HHS R01CA87538NCI NIH HHS U01 CA058860Wellcome Trust
6 · The paper itself

Abstract

Epithelial ovarian cancer (EOC) is the leading cause of death from gynecological malignancy in the developed world, accounting for 4% of the deaths from cancer in women. We performed a three-phase genome-wide association study of EOC survival in 8,951 individuals with EOC (cases) with available survival time data and a parallel association analysis of EOC susceptibility. Two SNPs at 19p13.11, rs8170 and rs2363956, showed evidence of association with survival (overall P = 5 × 10⁻⁴ and P = 6 × 10⁻⁴, respectively), but they did not replicate in phase 3. However, the same two SNPs demonstrated genome-wide significance for risk of serous EOC (P = 3 × 10⁻⁹ and P = 4 × 10⁻¹¹, respectively). Expression analysis of candidate genes at this locus in ovarian tumors supported a role for the BRCA1-interacting gene C19orf62, also known as MERIT40, which contains rs8170, in EOC development.

Indexed as

Genetic Predisposition to DiseaseGenome, HumanGenome-Wide Association StudyAdaptor Proteins, Signal TransducingAdenocarcinoma, Clear CellAdenocarcinoma, MucinousBiomarkers, TumorCase-Control StudiesChromosomes, Human, Pair 19Cystadenocarcinoma, SerousEndometrial NeoplasmsFemaleGene Expression ProfilingGenotypeHumansMiddle AgedAdaptor Proteins, Signal TransducingBABAM1 protein, humanBiomarkers, Tumor

Identifiers

PMID20852633
PMCPMC3125495
OpenAlexW1985742486

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.